Key result
De novo PRKACA duplication is linked to PPNAD and thyroid carcinoma in a young female.
Case Report (n=1)
Germline duplication of the PRKACA gene at 19p13.12 can underlie primary pigmented nodular adrenocortical disease and Cushing syndrome.
Answers are grounded in this paper and cite their sources.
Does not support routine PRKACA testing in PPNAD; leaves open its role pending replication in larger cohorts.
Rare pathogenic variants affecting components of the evolutionary conserved cAMP/protein kinase A (PKA) signalling pathway are implicated in a spectrum of adrenocortical disorders. Germline inactivating PRKAR1A variants leading to constitutive PKA activation, underlie primary pigmented nodular adrenocortical disease (PPNAD) in Carney complex. More recently, several patients with PPNAD and other types of bilateral nodular adrenal disease (BNAD) have been diagnosed with rearrangements in chromosome 19 at band p13.12, resulting in copy number gains of the entire PRKACA gene. Here, we report the identification of a 19p13.12 rearrangement, resulting in a duplication of the PRKACA gene, in a 32-year-old female from whom the genetic aetiology remained unknown for 20 years. Furthermore, we provide an updated overview of patients with PRKACA germline copy number gains that have previously been reported in the literature.
No takes yet. Share an insight, caveat, or question.
Broekema et al. (2026) conducted a case report in Primary pigmented nodular adrenocortical disease (PPNAD) (n=1). PRKACA duplication at 19p13.12 was evaluated on Identification of genetic etiology. A de novo tandem duplication in 19p13.12, resulting in three copies of the PRKACA gene, was identified as the genetic cause of PPNAD and thyroid carcinoma in a 32-year-old female.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: